Erasca reports 57% uORR at 8 weeks for ERAS-0015 in KRAS G12X PDAC; plans pivotal trials in 2027

Erasca, Inc.

57% uORR at 8 weeks in 2L+ KRAS G12X PDAC at 32 mg QD RDE (N=7).
Safety: mostly low-grade TRAEs, no DLTs, no discontinuations due to TRAEs; median relative dose intensity 100%.
Combination with panitumumab in mCRC: no DLTs in 16 mg cohort; dose escalation ongoing.
Plans: registration-enabling trial in NSCLC 2L+ in H1 2027; Phase 3 pivotal in PDAC 1L in 2027; Phase 3 pivotal in RAS-mutant NSCLC in H2 2027/H1 2028.
One Grade 3 pneumonitis event progressed to Grade 5 after withdrawal of supportive care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.